新闻
6 小时之前
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
快速通道临床结果突破性疗法
2024-07-05
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
上市批准申请上市优先审批免疫疗法
2024-07-05
Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
免疫疗法临床结果上市批准
2024-07-05
恒瑞医药两款1类创新药获批临床
申请上市临床研究临床申请
2024-07-05
安圣莎®术后辅助治疗适应症在华获批,重塑ALK阳性早期肺癌治疗新格局
上市批准临床结果
2024-07-05
延长癌症总生存期!强生/传奇生物CAR-T疗法3期积极结果公布
细胞疗法免疫疗法临床结果ASH会议
2024-07-05
国产首款:成都所四价HPV疫苗申报上市
抗体药物偶联物疫苗
2024-07-05
IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
上市批准
2024-07-04
创新FGFR2抑制剂获FDA快速通道资格,治疗这种癌症
快速通道免疫疗法抗体药物偶联物
2024-07-04
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
临床结果生物类似药